← Back to Search

Women for Nephrotic Syndrome

N/A
Recruiting
Led By C. Noel Bairey Merz, MD, FACC
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 years
Awards & highlights

Summary

The Women's Ischemia Study Evaluation (WISE), a cohort study of over 1000 women, has made many contributions to the understanding of cardiovascular disease. A milestone acknowledged in the 2011 AHA Herrick Lecture is the role of Coronary Microvascular Dysfunction (CMD) in women with symptoms/signs of ischemia without obstructive coronary artery disease (CAD). While in 1996, CMD was considered "an imaging artifact", in 2013, it is a widely accepted as a pathophysiologic process requiring systematic cohesive scientific pursuit. CMD is prevalent, associated with adverse clinical outcomes, poor quality of life and healthcare costs rivaling obstructive CAD. There are 2-3 million US women with CMD, and 100,000 new cases projected annually placing CMD prevalence, morbidity and costs higher than all female reproductive cancers combined. Among women with ischemia, preserved ejection fraction and no obstructive CAD, it has been observed that there are relatively more new onset heart failure (HF) hospitalizations than nonfatal myocardial infarction (MI). It has been hypothesized that CMD contributes to left ventricular (LV) diastolic dysfunction and subsequent heart failure with preserved ejection fraction (HFpEF). Preliminary data further suggests that left ventricular diastolic dysfunction is linked to CMD via a mechanism of augmentation and/or perpetuation by cardiomyocyte fat accumulation. HFpEF is prevalent in women and older men, but poorly understood. Mechanistic understanding is critical to HFpEF intervention and guideline development. The study hypotheses are as follows: 1. Risk factor conditions (hypertension, dyslipidemia, dysglycemia, loss of estrogen) promote an inflammatory and pro-oxidative state making the microvasculature vulnerable; 2. Vulnerable coronary microvasculature becomes dysregulated (sympathetic nervous system activation, endothelial dysfunction, changes in vascular smooth muscle activation, spasm) causing repeated episodes of transient ischemia; 3. Repeated ischemia-reperfusion episodes facilitate preconditioning with preservation of cardiomyocyte contractile and microvascular function against ischemic injury; 4. Ischemia-reperfusion and preconditioning lead to cardiomyocyte fat accumulation and relaxation impairment resulting in diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF).

Eligible Conditions
  • Nephrotic Syndrome
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Persistent Chest Pain Symptoms: SAQ
Persistent Chest Pain Symptoms: WISE female angina Questionnaire
Quality of Life Outcomes: DASI
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Women or menExperimental Treatment5 Interventions
Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
Group II: WomenExperimental Treatment6 Interventions
Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac Magnetic Resonance Imaging
2020
Completed Phase 2
~260
Coronary Angiography
2017
Completed Phase 3
~11270

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
509 Previous Clinical Trials
165,693 Total Patients Enrolled
6 Trials studying Nephrotic Syndrome
477 Patients Enrolled for Nephrotic Syndrome
C. Noel Bairey Merz, MD, FACCPrincipal InvestigatorCedars-Sinai Medical Center
3 Previous Clinical Trials
1,613 Total Patients Enrolled
1 Trials studying Nephrotic Syndrome
180 Patients Enrolled for Nephrotic Syndrome
~22 spots leftby Sep 2025